The Ensign Group is a post-acute care company that buys underperforming skilled nursing and senior living facilities, fixes them, and converts the fix into occupancy, reimbursement quality, and earnings. The second quarter of 2026 is the strongest expression of that model in years. Consolidated revenue reached 1.44 billion. That was a 17.3 percent gain over the year-ago quarter, and diluted GAAP earnings per share came in at 1.68. The company also raised its full-year adjusted earnings guidance. The new range is 7.75 to 7.85 per diluted share, up from the prior range. Revenue guidance was lifted to 5.87 billion to 5.92 billion.
The share price near the top of its two-year range has already absorbed a large share of that story. The market is paying for a transformation record that is now well documented, for an acquisition pipeline that added 102 operations since 2024, and for a guidance culture that has repeatedly moved the number up. The open question is whether the occupancy and skilled mix gains that are currently running at same facilities can keep outrunning the dilutive entry points of the new portfolio, and whether reimbursement policy, particularly the state directed payment phase down tied to federal Medicaid changes, leaves enough room in the margin structure for the premium multiple to hold.
The second quarter also marked a step up in capital return. The board approved a new repurchase program of 100 million. The company deployed the first 40 million tranche in June at an average price of 155.54 per share. The board approved a second authorization tranche the same month. That combination, a raised guide and an aggressive buyback, is the clearest signal yet that management believes the market is undervaluing the stabilized earnings base.